Eighth Annual Awards Honors New and Inspiring Solutions to the
Most Daunting Challenges of Today
SAN
DIEGO, May 15, 2024 /PRNewswire-PRWeb/ --
Seraphina Therapeutics is proud to announce its recognition as a
2024 World Changing Idea in Fast Company's Wellness Category. This
award honors the businesses that are developing creative solutions
to the most pressing issues of our time.
Seraphina's co-founders, Drs. Eric and
Stephanie Venn-Watson, are a husband-wife,
physician-veterinarian team and military family who discovered
C15:0 as the first essential fatty acid to be found in over 90
years, since omega-3. C15:0 (pentadecanoic acid) is an odd-chain
saturated fatty acid present in trace amounts in whole dairy fat,
as well as some types of fish and plants. Seraphina developed the
world's first pure, bioavailable, and vegan-friendly C15:0
ingredient (FA15), which is the sole ingredient in their
supplement, fatty15.
This 2024 World Changing Idea recognition was due to the team's
recent discovery of FA15 as a healthspan supporting nutrient that
outperformed leading longevity-enhancing compounds, rapamycin,
metformin, and acarbose. Specifically, as published in Nutrients,
FA15 had 36+ clinically relevant cellular benefits to protect
long-term metabolic, liver, immune and heart health, which was
better than the other three longevity-enhancing candidates.
Further, pure FA15 has been shown to enhance the human longevity
regulating pathway and successfully target 6 of the 12 "hallmarks
of aging", which define how we age at the cellular level.
"We are excited to be recognized as a Fast Company World
Changing Idea for the second time," said Dr. Stephanie Venn-Watson, Seraphina's CEO. "Our
journey towards improving global health by replenishing
individuals' essential C15:0 levels, starting with fatty15, has
just begun."
Population-wide C15:0 levels have been declining due to lowered
dietary intake of C15:0 from dairy fat, as well as natural declines
in C15:0 that occur with aging. Mounting evidence supports that
nutritional C15:0 deficiencies may be accelerating aging and
contributing to the global rise in type 2 diabetes, heart disease,
and fatty liver disease, especially among younger people. On the
flip side, people living in High Longevity Zones (also called Blue
Zones), have significantly higher C15:0 levels compared to other
populations. Seraphina continues to work with the global medical,
scientific, and nutrition communities to help get C15:0 back into
people's lives.
About Seraphina Therapeutics. Inc.
Seraphina Therapeutics, Inc. is a health and wellness company
dedicated to advancing global health through the discovery of
essential fatty acids and micronutrient therapeutics. Through
rigorous breakthrough science, the company develops fatty acid
supplements, food fortifiers, and nutritional interventions to
strengthen cells, keep mitochondria working and advance cellular
homeostasis to counter age-related breakdown. With its team of
industry-leading scientists, Seraphina Therapeutics challenges
long-held approaches to nutrition, enabling the creation of novel
health products designed to support quality of life. For more
information, please visit DiscoverC15.com and fatty15.com.
Media Contact
Fatty15 Press Office, Fatty15, 1 619-407-9225,
press@fatty15.com, https://www.fatty15.com
View original
content:https://www.prweb.com/releases/seraphina-therapeutics-groundbreaking-discovery-of-c150-as-a-leading-longevity-nutrient-recognized-as-a-2024-fast-companys-world-changing-idea-302146525.html
SOURCE Seraphina Therapeutics